Monopar Therapeutics Inc. (MNPR)
$73.10+1.42%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $490M
- Beta
- 1.51
- P/E (TTM)
- -31.24
- Short % float
- 26.09%
- Days to cover
- 6.0
- SI change
- +28.7%
- 1W
- -12.75%
- 1M
- -29.93%
- vs SPY 1W
- -11.77%
- vs SPY 1M
- -31.80%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on MNPR?
- LOPJLB’s latest quantitative signal on Monopar Therapeutics Inc. (MNPR) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is MNPR in?
- Monopar Therapeutics Inc. (MNPR) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Monopar Therapeutics Inc. (MNPR) do?
- Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expre…